These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

862 related articles for article (PubMed ID: 31492651)

  • 1. Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial.
    Comi G; Kappos L; Selmaj KW; Bar-Or A; Arnold DL; Steinman L; Hartung HP; Montalban X; Kubala Havrdová E; Cree BAC; Sheffield JK; Minton N; Raghupathi K; Ding N; Cohen JA;
    Lancet Neurol; 2019 Nov; 18(11):1009-1020. PubMed ID: 31492651
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial.
    Cohen JA; Comi G; Selmaj KW; Bar-Or A; Arnold DL; Steinman L; Hartung HP; Montalban X; Kubala Havrdová E; Cree BAC; Sheffield JK; Minton N; Raghupathi K; Huang V; Kappos L;
    Lancet Neurol; 2019 Nov; 18(11):1021-1033. PubMed ID: 31492652
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and efficacy of the selective sphingosine 1-phosphate receptor modulator ozanimod in relapsing multiple sclerosis (RADIANCE): a randomised, placebo-controlled, phase 2 trial.
    Cohen JA; Arnold DL; Comi G; Bar-Or A; Gujrathi S; Hartung JP; Cravets M; Olson A; Frohna PA; Selmaj KW;
    Lancet Neurol; 2016 Apr; 15(4):373-81. PubMed ID: 26879276
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of Ozanimod on Symbol Digit Modalities Test Performance in Relapsing MS.
    DeLuca J; Schippling S; Montalban X; Kappos L; Cree BAC; Comi G; Arnold DL; Hartung HP; Sheffield JK; Liu H; Silva D; Cohen JA
    Mult Scler Relat Disord; 2021 Feb; 48():102673. PubMed ID: 33454584
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study.
    Khatri B; Barkhof F; Comi G; Hartung HP; Kappos L; Montalban X; Pelletier J; Stites T; Wu S; Holdbrook F; Zhang-Auberson L; Francis G; Cohen JA;
    Lancet Neurol; 2011 Jun; 10(6):520-9. PubMed ID: 21571593
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of ozanimod in multiple sclerosis: Dose-blinded extension of a randomized phase II study.
    Cohen JA; Comi G; Arnold DL; Bar-Or A; Selmaj KW; Steinman L; Havrdová EK; Cree BA; Montalbán X; Hartung HP; Huang V; Frohna P; Skolnick BE; Kappos L;
    Mult Scler; 2019 Aug; 25(9):1255-1262. PubMed ID: 30043658
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis.
    Cohen JA; Barkhof F; Comi G; Hartung HP; Khatri BO; Montalban X; Pelletier J; Capra R; Gallo P; Izquierdo G; Tiel-Wilck K; de Vera A; Jin J; Stites T; Wu S; Aradhye S; Kappos L;
    N Engl J Med; 2010 Feb; 362(5):402-15. PubMed ID: 20089954
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Methylprednisolone in combination with interferon beta-1a for relapsing-remitting multiple sclerosis (MECOMBIN study): a multicentre, double-blind, randomised, placebo-controlled, parallel-group trial.
    Ravnborg M; Sørensen PS; Andersson M; Celius EG; Jongen PJ; Elovaara I; Bartholomé E; Constantinescu CS; Beer K; Garde E; Sperling B
    Lancet Neurol; 2010 Jul; 9(7):672-80. PubMed ID: 20542736
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial.
    Calabresi PA; Radue EW; Goodin D; Jeffery D; Rammohan KW; Reder AT; Vollmer T; Agius MA; Kappos L; Stites T; Li B; Cappiello L; von Rosenstiel P; Lublin FD
    Lancet Neurol; 2014 Jun; 13(6):545-56. PubMed ID: 24685276
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase III SUNBEAM and RADIANCE PART B trials for Ozanimod in relapsing multiple sclerosis demonstrate superiority versus interferon-β-1a (Avonex
    Koscielny V
    Neurodegener Dis Manag; 2018 Jun; 8(3):141-142. PubMed ID: 29943693
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ozanimod for the treatment of relapsing remitting multiple sclerosis.
    Rasche L; Paul F
    Expert Opin Pharmacother; 2018 Dec; 19(18):2073-2086. PubMed ID: 30407868
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial.
    Kappos L; Li D; Calabresi PA; O'Connor P; Bar-Or A; Barkhof F; Yin M; Leppert D; Glanzman R; Tinbergen J; Hauser SL
    Lancet; 2011 Nov; 378(9805):1779-87. PubMed ID: 22047971
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative safety and efficacy of ozanimod versus fingolimod for relapsing multiple sclerosis.
    Swallow E; Patterson-Lomba O; Yin L; Mehta R; Pelletier C; Kao D; Sheffield JK; Stonehouse T; Signorovitch J
    J Comp Eff Res; 2020 Mar; 9(4):275-285. PubMed ID: 31948278
    [No Abstract]   [Full Text] [Related]  

  • 14. Plasma neurofilament light chain concentrations as a biomarker of clinical and radiologic outcomes in relapsing multiple sclerosis: Post hoc analysis of Phase 3 ozanimod trials.
    Harris S; Comi G; Cree BAC; Arnold DL; Steinman L; Sheffield JK; Southworth H; Kappos L; Cohen JA;
    Eur J Neurol; 2021 Nov; 28(11):3722-3730. PubMed ID: 34292643
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pegylated interferon β-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study.
    Calabresi PA; Kieseier BC; Arnold DL; Balcer LJ; Boyko A; Pelletier J; Liu S; Zhu Y; Seddighzadeh A; Hung S; Deykin A;
    Lancet Neurol; 2014 Jul; 13(7):657-65. PubMed ID: 24794721
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trial.
    Reich DS; Arnold DL; Vermersch P; Bar-Or A; Fox RJ; Matta A; Turner T; Wallström E; Zhang X; Mareš M; Khabirov FA; Traboulsee A;
    Lancet Neurol; 2021 Sep; 20(9):729-738. PubMed ID: 34418400
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial.
    Coles AJ; Twyman CL; Arnold DL; Cohen JA; Confavreux C; Fox EJ; Hartung HP; Havrdova E; Selmaj KW; Weiner HL; Miller T; Fisher E; Sandbrink R; Lake SL; Margolin DH; Oyuela P; Panzara MA; Compston DA;
    Lancet; 2012 Nov; 380(9856):1829-39. PubMed ID: 23122650
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial.
    Cohen JA; Coles AJ; Arnold DL; Confavreux C; Fox EJ; Hartung HP; Havrdova E; Selmaj KW; Weiner HL; Fisher E; Brinar VV; Giovannoni G; Stojanovic M; Ertik BI; Lake SL; Margolin DH; Panzara MA; Compston DA;
    Lancet; 2012 Nov; 380(9856):1819-28. PubMed ID: 23122652
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alemtuzumab versus interferon beta 1a for relapsing-remitting multiple sclerosis.
    Zhang J; Shi S; Zhang Y; Luo J; Xiao Y; Meng L; Yang X
    Cochrane Database Syst Rev; 2017 Nov; 11(11):CD010968. PubMed ID: 29178444
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alemtuzumab for multiple sclerosis.
    Riera R; Porfírio GJ; Torloni MR
    Cochrane Database Syst Rev; 2016 Apr; 4(4):CD011203. PubMed ID: 27082500
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 44.